Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 7Phase 3 5Phase 1 5Phase NA 3Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 18Thoracic 13Gastrointestinal 13Genitourinary 9Lymphoid 5Head & Neck 5Gynecologic 5Other hematologic neoplasm 4Plasma cell 3Other solid neoplasm 3Endocrine 2Classical hematology 2Dermatologic 1

Conditions

Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Advanced Endometrial Cancer 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 95Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Injections × Gynecologic × Clear all
NCT06828354 2026-04-20

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Gynecologic

Ovarian Neoplasms

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
398 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 3 Completed
140 enrolled 11 charts 1 FDA
Gynecologic

Ovarian Neoplasms

NCT00057720 2011-07-25

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 3 Completed
440 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡